THE Modern applied today, Tuesday, for an authorization in Europe vaccine of against him coronavirus in children aged 6-11 years.
The company said it had applied to the European Medicines Agency (EMA) for a single dose. 50 micrograms of its vaccine, at half, that is, the content used to vaccinate adults.
The European Union approved the vaccine in July for adolescents aged 12 to 17, but several countries, including Sweden, they stopped its use for young people aged 30 and younger due to rare side effects on the heart, reports Reuters.
In addition, the company announced in late October that the US drug regulator, o FDA, needs more time to complete its evaluation for the drug in the age group 12-17 years as it studies the risk of a type of inflammation in the heart called myocarditis after vaccination.
Moderna subsequently delayed applying to the US for the vaccine to children aged 6 to 11, while the FDA completes its assessment of vaccine use in the 12-17 age group.
Earlier in October, the US pharmaceutical industry said the vaccine was causing strong immune response in children aged six to 11 years and how it plans to submit the data to the judgment of regulators around the world soon.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
